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DesmosineAbstract Background: Desmosine (DES), a cross linking amino-acid unique to mature elastin is
expected to increase in proportion to the recruitment and activation of the inﬂammatory cells
induced by smoking, exposure to biomass fuel smoke etc., or during acute exacerbations of COPD.
Therefore, it could be investigated as a biomarker of the stable disease and during exacerbations.
Aim of the study: The study aimed to evaluate blood DES level in COPD exacerbation as well as
in the stable state, and to assess its relation to severity of exacerbation.
Methods: The study included 20 COPD patients and 20 healthy controls all individuals were
subjected to chest radiograph, spirometric pulmonary function, arterial oxygen saturation (SapO2),
arterial blood gases (ABG, patients only), and ELISA – based blood DES level assay which was
done once in controls and twice – in COPD patients, both during exacerbation and one month later
after being stable.
Results: DES level was more elevated, with high statistical signiﬁcance, in COPD patients (both
during exacerbation and in the stable state) compared to the control subjects, as well as it was sig-
niﬁcantly higher in COPD patients during exacerbation than in the same patients’ group after being
stable. The DES level showed signiﬁcant negative correlation with FEV1% in stable COPD and sig-
niﬁcant positive correlation with the severity of COPD exacerbation.
Conclusion: Blood DES level as a marker of elastin degradation was elevated in stable COPD
with more rise during exacerbation indicating that exacerbations could add more lung destruction
leading to further deterioration of the lung function.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction and rationale
Chronic obstructive pulmonary disease (COPD), a common
preventable and treatable disease is characterized by airﬂow
limitation that is usually progressive and associated with an
enhanced chronic inﬂammatory response in the airways and
the lung to noxious particles and gases. Exacerbations and
Table 2 Shows relationship between blood desmosine and
smoking status during acute exacerbation of COPD in patients’
group.
During exacerbation P value
Current
smoker
(N= 9)
Ex-smoker
(N= 11)
Blood desmosine
(ng/ml)
Mean ± SD 0.88 ± 0.284 0.67 ± 0.328 0.1 (NS)
NS: no statistically signiﬁcant difference.
Table 1 Age and sex distribution among both COPD patients’ and control groups.
Patients’ group (n= 20) Control group (n= 20) P-value
Age (years) Mean ± SD 66.4 ± 11.2 59.3 ± 13.6 0.07 (NS)
Range 48–92 45–73
Sex Male 17 85% 15 75% 0.7 (NS)
Female 3 15% 5 25%
Smoking index (pack year) Mean ± SD 55.6 ± 23.7 10.1 ± 4.2 <0.001 (HS)
NS: no statistically signiﬁcant difference.
Table 4 Correlation between blood desmosine level and some
clinical laboratory and spirometric characteristics in COPD
patients’ group.
Blood desmosine
R P-value
Age (years) 0.1 0.6 (NS)
BAP-65 score 0.58 0.007*
FEV1% of predicted 0.82 0.0001*
FVC% of predicted 0.79 0.0001*
FEV1/FVC% 0.72 0.001*
COPD stage 0.72 0.001*
NS: No statistically signiﬁcant difference.
* Statistically highly signiﬁcant difference.
570 S. Labib et al.comorbidities contribute to the overall severity in individual
patients [1].
The course of COPD is characterized by progressive lung
function decline and exacerbations leading to physiologic dete-
rioration and respiratory failure especially at advanced stages
of the disease [2]. An exacerbation of COPD is deﬁned as an
acute event characterized by a worsening of the patient’s respi-
ratory symptoms beyond normal day to day variations and
leads to a change in medication.
The best predictor of having frequent exacerbations (i.e.
greater than or equal to 2years) is a history of previously trea-
ted events; the risk of exacerbations also increases as the air-
ﬂow limitation worsens [3].
Desmosine (DES) and Isodesmosine (IDES) are cross link-
ing amino-acids unique to mature elastin, in conjunction with
microﬁbrils formed from tropoelastin [4]. Blood normally con-
tains fragments derived from tropoelastins and from degraded
cross-linked mature elastin (i.e. DES and IDES) [4].
These particles are expected to increase both in the blood
and urine in proportion to the recruitment and activation of
the inﬂammatory cells particularly neutrophil induced by
smoking, exposure to biomass fuel smoke etc., or during acute
exacerbations of COPD. Therefore, they could be measuredTable 3 Blood desmosine level among COPD patients’ and contro
Patients’ group
(exacerbation) (n= 20)
Desmosine (ng/ml) Mean ± SD 0.77 ± 0.32a
Range 0.2–1.6
a–c Indicate statistically signiﬁcant difference within groups (Bonferroni t
* Statistically highly signiﬁcant difference.and examined as biomarkers of the stable disease and during
exacerbations.
Aim of the study
The study aimed to evaluate blood desmosine level as a marker
of elastinolysis in acute exacerbation of COPD as well as in the
stable state of the disease, and to assess its relation to the sever-
ity of the exacerbation.
Subjects and methods
This case control and prospective study was conducted in the
Chest Unit, Internal Medicine Department, Suez Canal Uni-
versity, Ismailia, Egypt. Two groups of participants were
included in the study; the ﬁrst group included 20 patients with
COPD who were admitted through ER and chest clinic in
acute exacerbation. All of them met the criteria of the Global
Initiative for the Diagnosis of COPD (GOLD) [1]. Grading of
severity of the exacerbation was done using the BAP-65 score
[5] which included BUN level >25 mg/dl, altered sensorium,l groups.
Patients’ group
(stable state) (n= 20)
Control group
(n= 20)
P-value
0.37 ± 0.29b 0.063 ± 0.068c 0.001*
0–1.2 0–0.2
est).
00.2
0.4
0.6
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Figure 1 Shows non-signiﬁcant higher blood desmosine level in
current smokers than in ex-smokers in COPD patients during
acute exacerbation.
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Figure 2 Shows signiﬁcantly higher blood desmosine level (ng/
ml) in COPD patients during exacerbation compared to the same
group in the stable state. Patients’ group, during both exacerba-
tion and in the stable state, has highly signiﬁcant, higher level
compared to controls.
Figure 3 Shows non-signiﬁcant negative correlation between
blood desmosine (ng/ml) and age (years) in COPD patients.
Figure 4 Shows highly signiﬁcant positive correlation between
blood desmosine (ng/ml) and grade of severity of COPD exacer-
bation based on BAP-65 score.
Study of blood desmosine level 571and pulse rate >109beats/min. Patients younger than 65 years
were classiﬁed as grade 1, whereas those older than 65 years
without other risk factors were classiﬁed as class 2. The desig-
nation into risk classes 3, 4, 5 was based on whether the patient
had 1, 2 or 3 of the central risk factors respectively. The con-
trol group involved 20 healthy subjects who did not experience
recent (within two weeks) chest infection.
The following subjects were excluded:1) Age < 40 years.
2) Patients with history of pulmonary disease other than
COPD.
3) Chronic kidney and heart diseases.
All individuals were subjected to the following; complete
medical history and physical examination, frontal chest radio-
Figure 5 Shows highly signiﬁcant negative correlation between
blood desmosine (ng/ml) and FEV1% of predicted in patients with
COPD.
572 S. Labib et al.graph, ABG (patients group only), spirometric pulmonary
function testing, routine blood work (CBC, S.creatinine,
FBS, SGPT, etc.) and blood desmosine level which was also
remeasured in the patients’ group, one month after hospital
discharge when they became stable. Blood desmosine assay
employed the quantitative enzyme immune assay technique
using a colorimetric method (i.e. the color intensity increases
in proportion to the amount of desmosine) with a detection
range: 0.156–10 ng/ml (MyBioSource, San Diego, U.S.A.),
the minimum detectable level of human DES is <0.039 ng/ml.
Results
There are non-signiﬁcant differences between patients and con-
trols regarding sex and age with, highly signiﬁcant, higher
smoking index in patients with COPD.
Discussion
In the present study, the blood desmosine level was higher in
COPD patients whether in the stable state (0.37 ng/
ml ± 0.29) or during exacerbation (0.77 ng/ml ± 0.32) com-
pared to control subjects (0.063 ng/ml ± 0.069) with highly
signiﬁcant difference (p< 0.01 (Table 3, Fig. 2). Our results
were consistent with those of Attia et al. [6], who found a
higher blood desmosine level in COPD patients than in control
subjects, but with lower values than our values, especially dur-
ing exacerbation (0.34 ng/ml ± 0.04) which could be explained
by possible impaired urinary excretion in our patients causing
more elevation of blood desmosine as 35% of our patients
were in class V according to BAP-65 scoring for severity of
exacerbation of COPD [5] i.e. they had elevated BUN among
other risk factors. In the present study we did not concomi-
tantly measure urinary desmosine so that the total desmosinelevel (blood and urine) would be more indicative of elastin
turnover status. Huang et al. [7] found that the level was higher
in only 40% of COPD patients during exacerbation and not in
the stable state. Again these results are different from ours,
and this could reﬂect the small sample size and the higher score
of acute exacerbation severity in our studied patients’ group.
The present study also disclosed signiﬁcantly higher level of
blood desmosine in patients’ group during exacerbation
(0.77 ng/ml ± 0.32) compared to the same group after being
stable (0.37 ng/ml ± /dl) (Table 3, Fig. 2). These results are
in keeping with those of Fiorenza et al. [8], who found a higher
urinary desmosine concentration during acute exacerbation of
COPD compared to the stable state in the same patients’
group. These results suggest that COPD patients during acute
exacerbation might have increased elastin degradation which
results in more elastin-derived cross-linking amino acids
(DES and IDES) than in patients with the stable disease. This
probably reﬂects the increased number and activation of neu-
trophils within the lungs, occurring during an acute exacerba-
tion of COPD [9,10], which are responsible for the purulence
of the sputum and the high concentration of sputum serine
proteases such as neutrophil elastase [11]. Thus, it may be sup-
posed that the increased desmosine production in an exacerba-
tion of COPD is the result of acute damage to elastin in
airways and alveolar walls by neutrophil elastase, adding to
the ‘‘baseline’’ elastin degradation found in the stable COPD
[12]. Regarding the association between blood desmosine and
FEV1%, it had been found that FEV1% negatively correlated
with blood desmosine with statistically signiﬁcant difference
(r= 0.82 and P< 0.05) (Table 4, Fig. 5).
Previous studies, on the correlation between the desmosine
and lung function, gave conﬂicting results. Huang et al. [6] did
not observe a signiﬁcant correlation between FEV1% and
blood DES in patients with the stable disease, or during an
exacerbation of COPD. Gottlieb et al. [13], studied apparently
healthy smoking adult males and found signiﬁcantly higher
desmosine production in rapid FEV1 decliners than in slow
decliners, and a signiﬁcant correlation between desmosine pro-
duction and the rate of FEV1 decline over 6.3 years. In con-
trast, Boutin et al. [14], found signiﬁcantly lower levels of
desmosine production in COPD patients with rapid FEV1
decline compared with slow decliners over 15 years. However,
Attia et al. [6], found that the blood desmosine level was signif-
icantly but inversely correlated with FEV1%. The inconsistent
results of some studies could be explained by recruiting
patients with different underlying pathology of COPD (i.e.
predominantly chronic bronchitis and small airway disease
rather than emphysema).
In this study, we also investigated the association between
BAP-65 score [5] (Table 4, Fig. 4), that was used to grade
the severity of acute exacerbation of COPD and it was found
that there was statistically signiﬁcant positive correlation
between this score and blood DES level (r= 0.58 and
p< 0.05), so blood DES can be used as a biomarker of the
severity of acute exacerbation of COPD. However further
studies on a larger number of patients are needed with assess-
ment of the level in patients with the stable disease (i.e. base-
line) to be remeasured during and after an acute
exacerbation after being stable again, with and without thera-
peutic interventions [15–17]. This will give an objective and
real insight on the adverse effect of acute exacerbation(s) on
the lung parenchyma through elastin degradation.
Study of blood desmosine level 573The current study revealed higher but non-signiﬁcant val-
ues of blood DES level in current, compared to ex-smokers
(P> 0.05) with non-signiﬁcant correlation with the smoking
index in the former patients’ group (Table 2, Fig. 1). These
results are in agreement with those of others [6,7], and they
might reﬂect the fact that smoking causes COPD in a relatively
small percentage of patients [18] i.e. who are susceptible to the
deleterious effect of smoking causing signiﬁcant lung paren-
chymal destruction with more elastinolysis and hence more
DES and IDES production. The non-signiﬁcant difference
between current and ex-smokers could be explained by the per-
sistence of chronic inﬂammation after abstaining from smok-
ing in all but mild COPD patients. Linderberg et al. [19]
demonstrated strong positive correlation between age and
blood DES. In the current study the correlation was negative
with statistically non-signiﬁcant difference (r= 0.1,
P> 0.05) (Table 4, Fig. 3) which may suggest decreased elas-
tin turnover as part of the aging process.
Based on the results of the present study, it had been con-
cluded that the blood level of desmosine was elevated in
patients with stable COPD with further rise during acute exac-
erbations when compared to healthy control subjects. It can be
speculated that the rise of blood desmosine level during acute
exacerbation of COPD gives indirect evidence that these exac-
erbations could contribute to the severity of the disease by
causing more and more lung destruction with progressive
emphysematous changes and further deterioration of lung
function.
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